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Abstract 
 
Background and purpose 
The Efficacy of Nitric oxide in Stroke (ENOS) trial found that transdermal glyceryl 
trinitrate (GTN, a nitric oxide donor) lowered blood pressure but did not improve 
functional outcome in patients with acute stroke. However, GTN was associated with 
improved outcome if patients were randomised within 6 hours of stroke onset. 
 
Methods 
In this pre-specified subgroup analysis, the effect of GTN (5 mg/day for 7 days) 
versus no GTN was studied in 629 patients with intracerebral haemorrhage presenting 
within 48 hours and with systolic blood pressure >140 mmHg. The primary outcome 
was the modified Rankin Scale (mRS) at 90 days. 
 
Results 
Mean blood pressure at baseline was 172/93 mmHg and significantly lower (difference 
-7.5/-4.2 mmHg; both p< 0.05) on day 1 in 310 patients allocated to GTN as 
compared with 319 randomised to no GTN. No difference in the mRS was observed 
between those receiving GTN versus no GTN (adjusted odds ratio, OR for worse 
outcome with GTN 1.04, 95% confidence interval (CI) 0.78-1.37; p=0.84). In the 
subgroup of 61 patients randomised within 6 hours, GTN improved functional outcome 
with a shift in the modified Rankin Scale (OR 0.22, 95% CI 0.07-0.69, p=0.001). 
There was no significant difference in the rates of serious adverse events between 
GTN and no GTN. 
 
Conclusions 
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In patients with intracerebral haemorrhage within 48 hours of onset, GTN lowered 
blood pressure, was safe but did not improve functional outcome. Very early 
treatment might be beneficial but needs assessment in further studies. 
 
Clinical Trial Registration –URL: http://www.isrctn.com/ISRCTN99414122. Unique 
Identifier: 99414122. 
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INTRODUCTION 
Spontaneous intracerebral haemorrhage (ICH) is a severe form of stroke with more 
than two-third of survivors disabled at three months and less than one-half surviving 
the first year.1 High blood pressure (BP) is common in acute ICH and is associated 
independently with a worse outcome,2 in part mediated through expansion of the 
haematoma.3, 4 In the large INTERACT-2 trial, intensive BP lowering during the first 6 
hours was associated with a trend to improved functional outcome in comparison with 
guideline BP lowering.5 In contrast, in a subgroup analysis of patients with acute ICH 
enrolled into the Scandinavian Candesartan Acute Stroke Trial (SCAST), treatment 
with oral candesartan was associated with a worse functional outcome.6 Hence, the 
management of high BP in acute ICH remains uncertain. 
 
Transdermal glyceryl trinitrate (GTN), a nitric oxide donor is a candidate treatment for 
acute ICH because it can lower blood pressure without changing cerebral blood flow, 
has no negative effects on platelet function 7-9 and can be given to patients with 
dysphagia, a common clinical complication of stroke.10 The Efficacy of Nitric Oxide in 
Stroke trial (ENOS) assessed the safety and efficacy of blood pressure lowering with 
transdermal GTN), in 4,011 patients with acute stroke;11 nearly one-fifth of these 
presented with spontaneous ICH.11 Although the main analysis showed that GTN did 
not improve death or dependency at 90 days after acute ischaemic stroke or ICH, 
apparent benefit was observed in patients randomised within 6 hours of stroke 
onset.11 This result mirrors a result seen in the pre-hospital pilot Rapid Intervention 
with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT) where GTN was 
administered by paramedics within 4 hours of onset.10 In this pre-specified analysis,12 
we have further assessed the effect of GTN in the subgroup of patients randomised 
into the ENOS trial following ICH, both overall (here called ENOS-ICH) and within 6 
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hours; the time window of 6 hours matches that for recruitment into the INTERACT-2 
trial,5 and encompasses the time window studied in RIGHT.10 
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METHODS 
 
The ENOS trial protocol, statistical analysis plan, baseline data and main results have 
been published.11-14 In brief, ENOS compared the effect of transdermal GTN (5 mg 
daily) versus no GTN, given for one week, in patients with acute stroke 
(randomisation within 48 hours of ictus) and high systolic blood pressure (systolic BP 
140-220 mmHg). Patients taking antihypertensive drugs prior to their stroke were 
also randomised to continue or stop these temporarily for one week. During 
treatment, BP was measured daily using a validated automatic BP monitor (Omron 
705CP) supplied to each site.15 The trial was registered (ISRCTN99414122) and 
approved by the ethics committees and competent authorities in all participating 
countries as appropriate. Patients or relatives gave consent or proxy consent 
respectively. In the present analysis, we included all patients enrolled into ENOS with 
ICH (ENOS-ICH). 
 
Brain imaging 
Participants had a baseline CT or MRI scan as part of clinical care, usually before 
randomisation. Where possible, a second research CT or MRI was performed at day 
7+1 (end of treatment). Uncompressed DICOM, JPEG, PNG or GIF image files were 
sent to the coordinating centre, either uploaded via a secure website or on a CD. 
Images sent on film were digitised using a VICOM digitiser. Scans were assessed 
centrally using validated scales by expert neuroradiologists or trained neurologists 
(AA, LC, AC, JB, RD, PK, JW), for the presence of haemorrhage, its location in the 
brain, presence and amount of mass effect, presence of blood in the subarachnoid 
space or ventricles, and underlying changes in the brain including cerebral atrophy,16 
leukoaraiosis,16 and presence of old lesions. 
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Haematoma volume (measured manually by ABC/2 formula 17 using Osirix software 18 
on a 26 inch Apple iMac), shape and density (using an ordered 5-point categorical 
scale),19 shape index (perimeter of haematoma/4∏ x area),20 density index (standard 
deviation/mean attenuation),21 and presence of blood in the subarachnoid space or 
ventricles using the Graeb score and its modified version 22, 23 were also measured. All 
imaging assessments were performed by KK masked to clinical data and treatment 
assignment. 
 
Outcomes 
The primary outcome was functional outcome assessed using the modified Rankin 
Scale (mRS) at 90 days after randomisation. Secondary outcomes studied at day 90 
included activities of daily living (Barthel Index, BI 24); cognition (modified telephone 
Mini-Mental State Examination, t-MMSE 25); and Telephone Interview for Cognition 
Scale, (TICS-M 26); health-related quality of life (European Quality of Life-5 
dimensions-3 level, EQ-5D,27 from which health utility status, HUS, was calculated 28 
and mood (short Zung Depression Score, ZDS 29). Safety outcomes comprised all-
cause mortality and case-specific fatality, early neurological deterioration (defined as 
a decrease of at least 5 points or decrease in consciousness of more than 2 points 
from baseline to day 7 on the Scandinavian Stroke Scale, SSS), recurrent stroke by 
day 7, symptomatic hypotension, hypertension,11 and serious adverse events. 
Outcomes at day 90 were assessed via telephone by trained investigators at national 
coordinating centres who were masked to treatment allocation. 
 
Analyses 
Statistical analysis was performed by intention-to-treat and followed the trial’s 
statistical analysis plan and analysis approaches used in the primary publication.11, 12 
Analyses were performed for all patients with ICH in ENOS, and separately for those 
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with ICH who were randomised within 6 hours of onset. Data are shown as number 
(%), median [interquartile range], or mean (standard deviation). Patients who died 
were allocated an extreme score: -5: Barthel Index; EQ-VAS -1: EQ-VAS, SSS 0, t-
MMSE, TICS-M, verbal fluency; 0: health utility status (derived from EQ-5D); 6: mRS 
and 102.5: Zung Depression Scale.11, 30 Comparisons between the treatment groups 
were performed with binary logistic regression, ordinal logistic regression, Cox 
proportional regression, or multiple linear regression. Statistical models were adjusted 
for prognostic baseline covariates: age, systolic BP, SSS score, time from symptom 
onset to randomisation, haematoma volume and treatment assignment (GTN vs no 
GTN). Odds ratio, hazard ratio or mean difference, with 95% confidence intervals, are 
given and statistical significance was set at p<0.05. Heterogeneity of treatment effect 
was assessed by including an interaction term in adjusted models. Analyses were 
performed using SPSS (version 21) on an Apple Mac. 
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RESULTS 
 
Baseline characteristics 
Between July 2001 and October 2013, a total of 629 participants with ICH were 
enrolled in the trial; 310 participants were randomly assigned to receive GTN and 319 
participants to no GTN (Table 1). Baseline characteristics were well matched between 
the two groups. The average age was 67 years; 66% of patients were male; 54% 
were enrolled from the UK; mean time from onset to recruitment 25 hours; and mean 
stroke severity 30.5 (s.d.12.4) on the Scandinavian Stroke Scale (SSS), equivalent to 
National Institute of Health Stroke Scale (NIHSS) 12.6 (5.3).31 
 
A majority (71%) of patients had their baseline scans performed within 12 hours of 
onset (Table 1). 87% of haemorrhages were deep-seated in the lacunar and striato-
capsular brain regions, most haematomas (63%) caused mass effect (moderate or 
extreme swelling), and many (67%) patients had leukoaraiosis. Evidence of a 
previous stroke was present in 50% of patients and brain atrophy was seen in 62% of 
the available scans. The mean haematoma volume was 13.3 cm3, and 153 (26%) of 
patients had an intraventricular haemorrhage (IVH). Additional information on 
baseline neuroimaging is given in Supplementary Table I. 
 
Blood pressure 
Mean BP at baseline was 172.1/93.4 mmHg and fell in both treatment groups over the 
first week. Following the first dose of GTN versus no GTN, BP was significantly lower 
by 7.5/4.2 mmHg (p=0.02/0.05 respectively); BP did not differ thereafter 
(Supplementary Figure I). 
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Clinical outcomes 
At day 90, the median mRS was 3 [IQR 2] in both the GTN and no GTN groups and 
did not differ in an adjusted analysis, common OR 1.04 (0.78-1.38) (Table 2, Figure 
1) or unadjusted analysis (data not shown). A test of ‘goodness-of-fit’ showed that 
the assumption of proportional odds was not violated (p=0.09). When assessed in 
subgroups defined by baseline clinical or neuroimaging factors, there were significant 
interactions between treatment and mRS for time to randomisation and stroke 
subtype (Supplementary Figures II and III). 
 
The cumulative risk of all causes of death during follow up did not differ between GTN 
and no GTN (adjusted hazard ratio 1.02, 95% CI 0.67-1.56, p=0.92; Supplementary 
Figure IV). There were no significant differences between the two groups in any of the 
secondary outcomes studied at days 7 or 90, including measures of disability, 
cognition, mood and quality of life (Table 2). The number of patients with a serious 
adverse event during follow-up did not differ between the treatment groups (24.2% 
vs. 21.9%, p=0.50) (Supplementary Table II). 
 
Relationship between baseline neuroimaging and mRS at day 90 
Table 3 shows the association between baseline neuroimaging characteristics and the 
primary outcome of mRS. Imaging measures that were significantly associated with 
outcome on both univariate and co-variate-adjusted analyses comprised the presence 
of intraventricular haemorrhage or atrophy, irregular haematoma shape and 
heterogeneous density. 
 
 
Patients randomised within 6 hours 
13 
 
Of the 629 patients with ICH, 61 (9.7%) participants were randomised within 6 hours; 
the average time to treatment was 4.4 (1.2) hours (Table 1). Patients were less likely 
to be enrolled in Asia or other non-UK countries, had a larger initial haemorrhage 
volume (mean 16.9 cm3) and were more likely to have IVH. 
 
Patients randomised to GTN (versus no GTN) had less impairment (higher SSS) at day 
7, and were less likely to die in hospital (Table 2). At day 90, GTN was associated with 
an improved functional outcome assessed using the mRS, manifest as a shift to less 
dependency (Table 2, Figure 2). Similarly, participants randomised to GTN were less 
disabled and had significantly better quality of life, mood and cognition scores (Table 
2). A trend to a reduction in death was seen in those patients randomised to GTN 
versus no GTN. (adjusted hazard ratio 0.19, 95% CI 0.03-1.01, p=0.0. 
 
Effect of GTN on haemorrhage measures at day 7 
One hundred and eighty-one patients had repeat brain imaging at one week for an 
assessment of the effect on haemorrhage characteristics (Table 4). Of these, 93 
patients received GTN and 88 to no GTN. When adjusted for baseline value, treatment 
with GTN was associated with a smaller reduction in haematoma volume (mean 
difference -4.3 cm3; p=0.06). 
 
 
14 
 
 
DISCUSSION 
 
In this subgroup of patients enrolled into the ENOS trial with ICH, functional outcome 
(assessed using the mRS) did not improve with GTN as compared to no GTN. This 
result mirrors that across the main study and is in spite of GTN reducing BP by 
7.5/4.2 mmHg. Further, no benefit was seen in key secondary outcomes, including 
activities of daily living, cognition, mood and quality of life. The absence of significant 
differences in the rates of deaths or serious adverse events between the two 
treatment groups suggests that treatment with GTN is safe. In a pre-specified analysis 
of the effect of treatment in patients randomised within 6 hours of ICH onset, GTN 
reduced early impairment; late dependency, disability, and death; and improved late 
cognition, mood and quality of life. 
 
These findings may have a number of explanations. First, patients could be 
randomised up to 48 hours after stroke onset. The large INTERACT-2 trial suggested 
that intensive BP lowering might be effective in patients enrolled within 6 hours 5 so 
the time window for recruitment into ENOS (mean 25.1 hours, maximum 48 hours) 
may have been too long. Supporting this is the observation that patients randomised 
within 6 hours of the onset of ICH into ENOS appeared to benefit with less 
dependency, disability, impairment and mood disturbance, and better cognition and 
quality of life. Very early BP lowering might help limit haematoma expansion.32, 33 
Second, the degree by which BP was lowered may have been too small; INTERACT-2 
achieved a reduction of 14 mmHg by 6 hours and showed a near-significant effect on 
functional outcome.5 Last, the duration of BP control in ENOS-ICH was limited to 3 
days as tachyphylaxis developed, a known feature of organic nitrate therapy. 
Nevertheless, these explanations are confounded by results from the subgroup of 
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patients with ICH randomised into the large SCAST trial,6 where oral candesartan was 
associated with a worse functional outcome.6 Here, treatment could be started up to 
30 hours after stroke onset and the difference in BP between active and placebo 
groups was smaller than in ENOS-ICH at 6.3/3.3 mmHg.  
 
The reduction in ICH volume in the GTN group (4 cm3) was similar to the effect 
observed in trials of rFVIIa although the agent was tested in earlier time windows.34, 35 
Mechanisms by which nitric oxide donors might reduce haematoma volume, and 
improve functional outcome if given early, include lowering BP, neuroprotection, and 
improving collateral blood flow. The latter two effects have been seen in experimental 
models of brain ischaemia36, 37 and may be of relevance after ICH. 
 
This subgroup analysis of ENOS has a number of strengths including recruitment of 
patients with ICH from multiple ethnic groups across five continents over a wide time 
window representative of routine clinical practice. Baseline neuroimaging and clinical 
outcomes were assessed masked to treatment assignment,13 follow-up was near 
complete,11 and the analysis was pre-specified.12 However, exclusion of patients with 
low or normal BP (systolic BP <140 mmHg) or very high (>220 mmHg), those with 
reduced consciousness (GCS<8), and those without motor signs, may have limited 
the external validity of the findings and especially the number of patients with large 
haematoma. 
 
In conclusion, this subgroup analysis of ENOS was neutral and did not identify any 
beneficial effect or harm in lowering BP with GTN in patients with acute ICH. 
Transdermal GTN appears to be safe and modestly effective in lowering BP in acute 
ICH, which can be useful in patients who are unable to swallow. The results in those 
patients randomised within 6 hours of ICH onset and recent guidelines 38, 39 support 
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ongoing or planned trials of lowering BP in the ultra-acute and hyper-acute periods 
after stroke, including the ATACH-2 trial of intravenous nicardipine,40 and RIGHT-2 
trial of GTN administered in the pre-hospital phase of stroke (ISTRCTN26986053). 
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Table 1. Baseline clinical and neuroimaging characteristics of all patients with intracerebral haemorrhage and those randomised 
within 6 hours. Data are number (%), median [interquartile range], or mean (standard deviation). Comparison of patients 
randomised within 6 hours versus those randomised later by Fisher’s exact test, Mann-Whitney U test or t test. 
 
 All GTN No GTN All <6 hours GTN No GTN 2p  
Clinical characteristics         
Number of patients (N) 629 310 319 61 29 32 -  
Age (years) 67.0 (12.4) 66.6 (12.0) 67.5 (12.7) 69.6 (12.5) 68.3 (11.4) 70.8 (13.5) 0.12  
Sex, male (%) 415 (66.0) 217 (70.0) 198 (62.1) 38 (62.3) 16 (55.2) 22 (68.8) 0.56  
Premorbid mRS>0 (%) 143 (22.7) 66 (21.3) 77 (24.1) 12 (19.7) 5 (17.2) 7 (21.9) 0.58  
Country (%)         
   UK 337 (53.6) 170 (54.8) 167 (52.4) 35 (57.4) 18 (62.1) 17 (53.1) 0.57  
   Asia 179 (28.5) 87 (28.1) 92 (28.8) 8 (13.1) 2 (6.9) 6 (18.8) 0.010  
   Other 113 (18.0) 53 (17.1) 60 (18.8) 18 (29.5) 9 (31.0) 9 (28.1) 0.028  
Time to randomisation (hours) 25.1 (13.0) 25.2 (13.1) 25.1 (12.9) 4.4 (1.2) 4.5 (1.1) 4.4 (1.3) -  
   <6 hours (%) 61 (9.7) 29 (9.4) 32 (10.0) - - - -  
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Smoking, current (%) 124 (20.4) 58 (19.3) 66 (21.4) 11 (18.0) 8 (27.6) 3 (9.4) 0.84  
Treated hypertension (%) 253 (40.2) 121 (39.0) 132 (41.4) 17 (27.9) 8 (27.6) 9 (28.1) 0.06  
Previous stroke (%) 79 (12.6) 41 (13.2) 38 (11.9) 10 (16.4) 6 (20.7) 4 (12.5) 0.39  
Ischaemic heart disease (%) 58 (9.2) 29 (9.4) 29 (9.1) 5 (8.2) 3 (10.3) 2 (6.3) 0.86  
Atrial fibrillation (%) 42 (6.7) 18 (5.8) 24 (7.5) 2 (3.3) 1 (3.4) 1 (3.1) 0.30  
Diabetes mellitus (%) 81 (12.9) 44 (14.2) 37 (11.6) 9 (14.8) 3 (10.3) 6 (18.8) 0.68  
TACS (%) 217 (34.5) 105 (33.9) 112 (35.1) 22 (36.1) 10 (34.5) 12 (37.5) 0.81  
SSS (/58) 30.5 (12.4) 30.1 (12.7) 30.9 (12.1) 30.1 (11.1) 30.3 (11.4) 30.0 (10.9) 0.81  
   NIHSS (/42), calculated 31  12.6 (5.3) 12.7 (5.5) 12.4 (5.2) 12.7 (4.8) 12.7 (4.9) 12.8 (4.7) 0.81  
Glasgow Coma Scale [/15] 15.0 [1.0] 15.0 [1.0] 15.0 [1.0] 15.0 [1.0] 15.0 [1.0] 15.0 [1.0] 0.43  
Blood pressure (mmHg)         
   Systolic 172.1 (19.4) 172.3 (18.9) 171.8 (19.9) 172.4 (16.8) 174.4 (19.2) 170.6 (14.4) 0.90  
   Diastolic 93.4 (13.9) 94.0 (13.1) 92.7 (14.6) 95.7 (12.2) 96.9 (13.4) 94.7 (11.1) 0.19  
Heart rate (bpm) 77.9 (14.5) 78.0 (14.6) 77.8 (14.4) 76.7 (13.6) 75.6 (15.5) 77.8 (11.8) 0.54  
Neuroimaging characteristics         
Available scan 587 (93.3) 296 (95.5) 291 (91.2) 57 (93.4) 28 (96.6) 29 (90.6) 0.89  
Time, onset-neuroimaging (%)         
22 
 
   <12 hours 414 (70.5) 220 (74.3) 194 (66.7) 53 (93.0) 27 (96.4) 26 (89.7) 0.78  
   >12 hours 173 (29.5) 76 (25.7) 97 (33.3) 4 (7.0) 1 (3.6) 3 (10.3) 0.50  
Adjudicated findings         
Haematoma location (%)         
   Lobar or cerebellar  † 79 (13.5) 42 (14.2) 37 (12.7)  12 (21.1) 7 (25.0) 5 (17.2) 0.76  
   Deep ‡ 508 (86.5) 254 (85.8) 254 (87.3) 45 (78.9) 21 (75.0) 24 (82.8) 0.75  
Mass effect (%)         
   No swelling or mild swelling 218 (37.2) 107 (36.3) 111 (38.1) 22 (38.6) 11 (39.3) 11 (37.9) 1.00  
   Moderate to severe swelling 299 (50.9) 155 (52.4) 144 (49.5) 28 (49.1) 14 (50.0) 14 (48.3) 0.90  
   Extreme swelling 70 (11.9) 34 (11.5) 36 (12.4) 7 (12.3) 3 (10.7) 4 (13.8) 1.00  
Leukoaraiosis (%) 391 (66.6) 199 (67.2) 192 (66.0) 38 (66.7) 19 (67.9) 19 (65.5) 1.00  
Previous stroke lesion (%) 291 (49.6) 149 (50.3) 142 (48.8) 33 (57.9) 18 (64.3) 15 (51.7) 0.21  
Atrophy (%) 366 (62.3) 186 (62.8) 180 (61.9) 40 (70.2) 19 (67.9) 21(72.4) 0.79  
Measured CT scan findings         
Volume, ABC/2 (cm3) 13.3 (16.5) 13.2 (15.3) 13.3 (17.7) 16.9 (30.5) 13.0 (14.4) 20.8 (40.7) 0.09  
With IVH (n=151, 25.7%)         
   Volume, ABC/2 (cm3) 18.5 (23.6) 17.7 (18.3) 19.2 (27.8) 31.8 (52.2) 21.1 (20.6) 40.1 (67.9) 0.018  
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   IVH Volume (ml) 4.8 (7.3) 4.2 (5.0) 5.4 (9.0) 7.2 (6.2) 7.1 (5.7) 7.3 (6.8) 0.18  
   Shape index20 2.4 (3.7) 2.2 (1.9) 2.6 (4.8) 3.2 (2.1) 3.3 (2.9) 3.2 (1.5) 0.35  
   Density index21 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.3 (0.1) 0.006  
   Graeb score (/12) 22 3.0 [2.0, 4.0] 3.0 [2.0, 4.0] 3.0 [2.0, 5.0] 4.0 [2.5, 6.0] 4.0 [2.0, 6.0] 4.0 [3.0, 6.0] 0.047  
Without IVH (n=436, 74.3%)         
   Volume, ABC/2 (cm3) 11.4 (12.6) 11.7 (13.9) 11.1 (11.2) 11.0 (11.8) 10.3 (11.1) 11.7 (12.9) 0.87  
   Shape index 20 1.2 (1.1) 1.2 (1.2) 1.2 (1.0) 1.4 (1.1) 1.3 (0.9) 1.5 (1.3) 0.73  
   Density index 21 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.2 (0.0) 0.2 (0.1) 0.52  
 
bpm: beats per minute; ICH: intracerebral haemorrhage; IVH: intraventricular haemorrhage; MCA: middle cerebral artery; mRS: 
modified Rankin scale; NIHSS: National Institute of Health Stroke scale; SSS: Scandinavian Stroke Scale; TACS: total anterior 
circulation syndrome. 
† Lobar: borderzone regions, cerebellar and or brainstem, ACA, PCA territory and MCA territory excluding striatocapsular regions 
‡ Deep: lacunar, MCA territory including striatocapsular regions 
Shape index was calculated as perimeter of haematoma/4∏ x surface area.20 Density index was determined as standard 
deviation/mean Hounsfield attenuation unit.  
 
 
24 
 
Table 2. Secondary outcomes at day 7 and day 90 for all patients with intracerebral haemorrhage and those randomised within 6 
hours. Data are number (%), mean (standard deviation) with 95% confidence intervals. Data are number of patients (%), mean 
(standard deviation) or median [interquartile range]. Comparison by logistic regression, ordinal regression or multiple regression 
with adjustment for age, sex, pre-morbid mRS, history of previous stroke, history of diabetes, severity, total anterior circulation 
syndrome, volume of intracerebral haemorrhage, systolic blood pressure, feeding status and time to randomisation. 
 
 
Outcome 
 
N 
 
 
GTN 
 
No GTN 
 
OR/MD 
(95% CI) 
 
2p 
 
<6 
hours 
 
GTN 
 
No GTN 
 
OR/MD 
(95% CI) 
 
2p 
 
Patients 629 310 319   61 29 32   
           
Day 7 (or discharge) 627 310 317        
Death (%) 627 10 (3.2) 10 (3.2) 1.03 (0.38, 2.88) 0.95 60 2 (6.9) 4 (12.5) - 1.00 
SSS (/58) 625 34.5 (15.4) 34.8 (16.0) 0.18 (-1.30, 
1.69) 
0.80 60 33.4 
(16.4) 
27.1 (19.6) 7.0 (1.0, 13.1) 0.033 
Recurrence (%) 626 8 (2.6) 4 (1.3) 2.43 (0.63, 9.29) 0.19 60 0 1 (3.1) - 1.00 
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Outcome 
 
N 
 
 
GTN 
 
No GTN 
 
OR/MD 
(95% CI) 
 
2p 
 
<6 
hours 
 
GTN 
 
No GTN 
 
OR/MD 
(95% CI) 
 
2p 
 
Hospital events 623 308 315   59 29 30   
Died in hospital (%) 623 28 (9.0) 32 (10.2) 0.92 (0.48, 1.76) 0.79 59 2 (6.9) 9 (30.0) - - 
Death or discharge to 
institution (%) 
623 121 (39.3) 131 (41.6) 0.84 (0.59, 1.22) 0.37 59 14 (48.3) 14 (46.7) 1.20 (0.32, 
4.43) 
0.79 
Day 90 623 309 316   61 29 32   
Death (%) 625 42 (13.6) 47 (14.9) 0.91 (0.55, 1.55) 0.76 61 2 (6.9) 12 (37.5) † 0.006 
mRS (/6) 625 3 [2] 3 [2] 1.04 (0.78, 1.38) 0.81 61 3 [2] 4 [4] 0.19 (0.06, 
0.59) 
0.004 
Barthel Index 622 62.3 (38.1) 61.4 (39.7) 1.26 (-3.65, 
6.17) 
0.62 61 66.9 
(36.4) 
46.9 (45.7) 20.71 
(6.34, 35.07) 
0.005 
t-MMSE 369 10 (7.2) 10.1 (7.4) 0.04 (-1.20, 
1.28) 
0.95 38 11.9 
(6.4) 
6.5 (8.3) 3.38 (-0.29, 
7.10) 
0.008 
TICS-M 370 11.9 (9.3) 12.7 (9.3) -0.64 (-2.20, 
0.93) 
0.43 39 16.6 
(9.1) 
7.1 (9.3) 7.17 (2.20, 
12.12) 
0.005 
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Outcome 
 
N 
 
 
GTN 
 
No GTN 
 
OR/MD 
(95% CI) 
 
2p 
 
<6 
hours 
 
GTN 
 
No GTN 
 
OR/MD 
(95% CI) 
 
2p 
 
Animal naming (/∞) 376 8.2 (7.8) 7.9 (7.4) 0.28 (-1.09, 
1.65) 
0.69 39 12.8 
(8.0) 
4.8 (7.3) 7.92 (2.93, 
12.92) 
<0.001 
ZDS (/100) 516 60.1 (24.2) 59.6 (24.3) 0.62 (-3.12, 
4.43) 
0.73 50 54.2 
(20.6) 
71.8 (28.6) -17.58 (-32.25,  
-3.01) 
<0.001 
HUS (/1) 621 0.45 (0.31) 0.46 (0.32) -0.01 (-0.05, 
0.03) 
0.60 61 0.53 
(0.3) 
0.53 (0.32) 0.19 (0.06, 
0.32) 
0.003 
EQ-VAS (/100) 543 54.6 (31.3) 55.1 (31.5) -0.44 (-5.16, 
4.27) 
0.85 57 60.9 
(26.7) 
40.4 (38.1) 21.28 (6.31, 
36.25) 
0.005 
Dead or institution 
(%) 
616 97 (31.4) 92 (29.1) 1.09 (0.72, 1.67) 0.68 61 13 (44.8) 14 (43.8) 0.51 (0.12, 
2.18) 
0.36 
 
BI: Barthel Index; EQ-VAS: EQ-Visual Analogue Scale; HUS: health utility status; ICH: intracranial haemorrhage; mRS: modified 
Rankin Scale; t-MMSE: Modified telephone Mini-Mental State Examination; SAE: serious adverse event; SBP: systolic blood 
pressure; SSS: Scandinavian Stroke Scale; TICS-M: Modified Telephone Interview for Cognitive Status; ZDS: Zung Depression 
Scale. † Fisher’s exact test 
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Table 3. Relationships between baseline imaging characteristics and functional outcome (modified Rankin Scale) at day 90. 
Results are odds ratio or mean difference with 95% confidence interval with comparison by logistic regression, ordinal regression 
or multiple regression; results are unadjusted, and adjusted for age, sex, severity (Scandinavian Stroke Scale) and time from 
stroke onset to imaging. 
  
Haematoma characteristics 
Univariate analyses 
OR/MD (95% CI) 
2p 
Co-variate adjusted 
OR/MD (95% CI) 
2p 
Haematoma location          
   Lobar 1.32 (0.87, 2.00) 0.19 1.31 (0.85, 2.03) 0.22 
   Deep 1.08 (0.76, 1.53) 0.68 0.84 (0.58, 1.21) 0.35 
Side of the brain                         
   Left  0.89 (0.67, 1.37) 0.40 0.76 (0.57, 1.01) 0.18 
   Right 1.10 (0.83, 1.45) 0.50 1.29 (0.97, 1.71) 0.09 
   Bilateral 2.41 (0.51, 11.50) 0.50  2.50 (0.41, 15.35) 0.32 
Mass effect  2.30 (1.61, 3.29) <0.0001 1.35 (0.93, 1.96) 0.18 
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Leukoaraiosis 2.14 (1.58, 2.90) <0.0001 1.34 (0.96, 1.86) 0.09 
Subarachnoid haemorrhage 2.22 (1.50, 3.28) <0.0001 1.47 (0.97, 2.21) 0.07 
Intraventricular haemorrhage 2.61 (1.86, 3.67) <0.0001 1.92 (1.35, 2.74) <0.0001 
Previous stroke lesion 1.19 (0.90, 1.59) 0.23 1.18 (0.88, 1.59) 0.28 
Remote haemorrhage 5.21 (1.11, 24.57) 0.04 1.39 (0.20, 9.03) 0.75 
Cerebral atrophy 2.70 (1.99, 3.66)     <0.0001 1.46 (1.14, 1.86) 0.002 
Volume ABC/2 (cm3) 1.02 (1.01, 1.03) <0.0001 1.01 (0.99, 1.02) 0.56 
Largest measured diameter (cm) 1.12 (1.07, 1.32) <0.001 0.88 (0.74, 1.04) 0.14 
Largest visual diameter  2.52 (1.69, 3.76) <0.0001 1.24 (0.81, 1.89) 0.32 
Haemorrhage shape (/5) 1.36 (1.23, 1.51) <0.0001 1.28 (1.15, 1.42) <0.0001 
Haemorrhage density (/5) 1.42 (1.27, 1.60) <0.0001 1.27 (1.13, 1.42) <0.0001 
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Haematoma characteristics 
Univariate analyses 
OR/MD (95% CI) 
2p 
Co-variate adjusted 
OR/MD (95% CI) 
2p 
Shape index  1.04 (0.98, 1.12) 0.22 1.03 (0.96, 1.11) 0.38 
Density index  1.00 (1.00, 1.01) 0.24 1.00 (0.99, 1.01) 0.45 
Haemorrhages with IVH         
   Volume (ABC/2 cm3) 1.01 (0.99, 1.02) 0.19 1.00 (0.97, 1.03) 0.94 
   IVH volume (cm3) 1.02 (0.98, 1.06) 0.40 1.01 (0.97, 1.06) 0.56 
   Haemorrhage shape (/5) 1.31 (1.03, 1.67) 0.026 1.42 (1.11, 1.82) <0.0001 
   Haemorrhage density (/5) 1.69 (1.37, 2.11) <0.0001 1.49 (1.19, 1.86) <0.0001 
   Graeb score (12) 1.07 (0.94, 1.22) 0.31 1.03 (0.90, 1.18) 0.67 
   Modified Graeb score (32) 1.03 (0.96, 1.10) 0.45 1.00 (0.94, 1.08) 0.80 
   Shape index 0.98 (0.91, 1.06) 0.63 0.99 (0.92, 1.08) 0.89 
   Density index 1.00 (1.00, 1.00) 0.13 1.00 (0.99, 1.00) 0.63 
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Table 4. Effect of treatment on neuroimaging measures at day 7 in 181 patients with a baseline scan prior to randomisation, for 
all patients with intracerebral haemorrhage. Data are number (%), median [interquartile range], or mean (standard deviation), 
and odds ratio or mean difference with 95% confidence intervals. Comparison by logistic regression, ordinal regression or multiple 
regression with adjustment for baseline value.  
 
Scan variables 
 
All Adjusted 
 
  GTN No GTN 
OR/MD 
2p 
(95% CI) 
Haematoma location  93 88 
  
Lobar (%) 10 (10.8) 11 (12.5) 1.24 (0.49, 3.15) 0.66 
Deep (%) 83 (89.2) 77 (42.5) 0.63 (0.10, 3.85) 0.61 
Intraventricular haemorrhage (%)  25  (26.9) 19 (21.6) 0.85 (0.43, 1.70) 0.65 
Subarachnoid haemorrhage (%) 7 (7.5) 11 (12.5) 0.50 (0.17, 1.49) 0.21 
Mass effect (%)  79 (84.9) 81 (92.0)   1.04 (0.72, 1.50) 0.84 
Brain tissue reduction (%) 53 (57.0) 59 (67.0) 0.51 (0.24, 1. 10) 0.09 
Cortical atrophy (%) 44 (47.3) 42 (47.7) 1.26 (0.47, 3.36) 0.64 
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Scan variables 
 
All Adjusted 
 
  GTN No GTN 
OR/MD 
2p 
(95% CI) 
Central atrophy (%) 48 (51.6) 58 (65.9) 0.92 (0.60, 2.10) 0.73 
Leukoaraiosis (%) 64 (68.8) 63 (71.6) 0.83 (0.37, 1.87) 0.66 
Previous stroke lesion (%) 41 (44.1) 51 (60.0) 0.57 (0.28, 1.16) 0.12 
Visual longest diameter (cm) 
  
0.66 (0.34, 1.27) 0.21 
    <3 38 (40.1) 36 (40.9) 
  
    3-5 46 (49.5) 28 (31.8) 
  
    5-8 6 (6.5) 20 (22.7) 
  
    >8 3 (3.2) 4 (4.5) 
  
Volume ABC/2 (cm3) 15.4 (16.0) 19.2 (21.4) -4.30 (-8.78, 0.23) 0.06 
Largest measured diameter 3.6 (1.3) 3.8 (1.6) -0.04 (-0.33, 0.25) 0.81 
Shape index 1.7 (0.8) 1.7 (1.0) -0.04 (-0.31, 0.24) 0.80 
Shape [/5] 2 [2,3] 2 [1,3] 0.14 (-0.19, 0.47) 0.41 
Density index 0.4 (0.7) 0.3 (0.5) 0.10 (-0.07, 0.28) 0.27 
Density [/5] 2 [1,3] 2 [1,3] 0.12 (-0.18, 0.43) 0.43 
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Scan variables 
 
All Adjusted 
 
  GTN No GTN 
OR/MD 
2p 
(95% CI) 
 
No IVH (n=137) 
    
 
  
Volume ABC/2(cm3) 14.7 (15.3) 18.4 (18.4) -4.52 (-9.05, 0.01) 0.05 
Shape index 1.5 (0.6) 1.7 (1.0) -0.12 (0.42, 0.17) 0.42 
Shape [/5] 2 [1,3] 2 [2,3] 0.04 (-0.31, 0.39) 0.82 
Density index 0.4 (0.9) 0.3 (0.7) 0.15 (-0.11, 0.41) 0.26 
Density [/5] 2 [1,3] 2 [1,3] 0.34 (-0.03, 0.71) 0.07 
With IVH (n=44)         
Volume ABC/2(cm3) 17.1(17.9) 18.4 (17.4) -0.64 (-8.53, 7.24) 0.87 
IVH volume (cm3) 3.0 (6.0) 3.7 (5.9) 0.52 (-4.96, 6.01) 0.85 
Shape index 2.0 (1.0) 2.1 (1.2) -0.12 (-0.79, 0.55) 0.73 
Shape [/5] 4 [3,5] 4 [3,5] 1.00 (0.50, 1.99) 0.99 
Density index 0.3 (0.1) 0.3 (0.1) -0.01 (-0.06, 0.04) 0.66 
Density [/5] 2 [1,3] 2 [1,3] 0.00 (-0.64, 0.63) 1.00 
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Scan variables 
 
All Adjusted 
 
  GTN No GTN 
OR/MD 
2p 
(95% CI) 
Graeb score 2.9 (1.8) 2.1 (1.3) 0.94 (-0.25, 2.12) 0.12 
Modified Graeb score 3.4 (2.7) 2.5 (2.2) 1.23 (-0.59, 3.05) 0.18 
 
 
35 
 
Figure 1. Distribution of modified Rankin scores for all 625 patients with intracerebral 
haemorrhage at day 90: glyceryl trinitrate versus no glyceryl trinitrate. Comparison 
by ordinal logistic regression adjusted for age, sex, premorbid mRS, history of 
previous stroke, history of diabetes, total anterior circulation syndrome, systolic blood 
pressure, feeding status, time to randomisation, and allocation to continue or stop 
pre-stroke antihypertensive drugs. Adjusted common odds ratio 1.04 (95% CI 0.78, 
1.38), p=0.81. 
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Figure 2. Distribution of modified Rankin scores for patients randomised within 6 
hours at day 90: glyceryl trinitrate (n=29) versus no glyceryl trinitrate (n=32). 
Comparison by ordinal logistic regression adjusted for age, sex, premorbid mRS, 
history of previous stroke, history of diabetes, total anterior circulation syndrome, 
systolic blood pressure, feeding status, time to randomisation, and allocation to 
continue versus stop pre-stroke antihypertensive drugs. Adjusted common odds ratio 
0.19 (95% CI 0.06, 0.59), p=0.004. 
 
 
 
 
 
